Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Latha Vairavan Sells 2,853 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) CFO Latha Vairavan sold 2,853 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.18, for a total value of $71,838.54. Following the transaction, the chief financial officer directly owned 87,754 shares in the company, valued at $2,209,645.72. This represents a 3.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Latha Vairavan also recently made the following trade(s):

• On Monday, February 2nd, Latha Vairavan sold 1,320 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.50, for a total value of $33,660.00.

Arcutis Biotherapeutics Stock Performance

Arcutis Biotherapeutics stock traded down $1.16 during midday trading on Tuesday, reaching $23.60. The stock had a trading volume of 1,889,246 shares, compared to its average volume of 1,373,037. The firm has a market capitalization of $2.93 billion, a PE ratio of -168.56 and a beta of 1.66. Arcutis Biotherapeutics, Inc. has a 12 month low of $11.86 and a 12 month high of $31.77. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57. The firm’s 50-day moving average price is $27.02 and its 200 day moving average price is $24.03.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. The firm had revenue of $129.50 million during the quarter, compared to analyst estimates of $110.79 million. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. As a group, research analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ARQT shares. Needham & Company LLC boosted their target price on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, February 26th. TD Cowen lifted their price target on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Mizuho decreased their price objective on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday. HC Wainwright increased their price objective on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Guggenheim lifted their target price on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $31.86.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis announced first participant enrollment in a Phase 1a/1b study of ARQ-234 (a CD200R agonist) to evaluate safety/tolerability in healthy volunteers and adults with moderate–severe atopic dermatitis — a clear pipeline positive that supports long-term growth potential. ARQ-234 trial enrollment
• Neutral Sentiment: Broker action: Mizuho lowered its price target from $37 to $35 but kept an “Outperform” rating — a modest near-term negative signal (slightly lower PT) but still positive conviction from the analyst. Mizuho note
• Neutral Sentiment: Fund reporting: Baron Health Care Fund published Q4 2025 activity (fund filings sometimes move small- and mid-cap biotechs), but the feed doesn’t specify a material position change in ARQT. Baron fund activity
• Neutral Sentiment: Short-interest data in the feed is inconsistent/erroneous (reports show 0 shares / NaN changes), so it provides no actionable signal to explain today’s move. Investors should treat those figures as unreliable until clarified by exchange data.
• Negative Sentiment: Insider selling: multiple company insiders sold shares on Feb 27–Mar 2 (including Todd Watanabe, Masaru Matsuda, Patrick Burnett, CFO Latha Vairavan and others). The aggregated sales total ~62,000 shares across named insiders (largest single sale ~37,349 shares by Watanabe). Insider sales can be interpreted as near-term negative sentiment or simple liquidity diversification — but the market often reacts negatively to clustered insider dispositions. Representative SEC filings: Todd Watanabe sale Watanabe Form 4, Masaru Matsuda filings Matsuda Form 4

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARQT. Johnson Investment Counsel Inc. purchased a new stake in shares of Arcutis Biotherapeutics in the third quarter worth $30,000. SBI Securities Co. Ltd. grew its position in Arcutis Biotherapeutics by 325.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after buying an additional 833 shares in the last quarter. Global Retirement Partners LLC bought a new position in Arcutis Biotherapeutics in the 4th quarter worth about $35,000. EverSource Wealth Advisors LLC raised its holdings in shares of Arcutis Biotherapeutics by 124.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after acquiring an additional 698 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after acquiring an additional 1,045 shares during the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.